Patients without comorbidities who received subcutaneous trastuzumab with their chemotherapy and endocrine therapy showed a significant improvement in emotional function, and reported that they were less upset by hair loss than the patients in the control group.
While the first trastuzumab biosimilar (Ontruzant) has recently launched in the European Union as an intravenously (IV) administered therapy, subcutaneously administered trastuzumab, available only as the reference product (Herceptin), has shown some possible advantages over IV therapy. A recent Spanish study demonstrated that subcutaneous administration of trastuzumab is associated with cost savings, reduced provider time spent administering the treatment, and reduced patient time in the treatment facility. The PrefHer study found that patients generally preferred to receive subcutaneous therapy versus the IV threapy.
Now, a new Greek study1 suggests that the subcutaneous administration does not have a negative impact on health-related quality of life (HRQOL) in patients with either early or metastatic breast cancer.
The authors of the prospective study identified 163 patients with HER2-positive breast cancer who were treated at 5 clinics in Athens between December 2015 and May 2016. Among these patients, 90 (55.21%) received subcutaneous trastuzumab, while 21 received intravenous trastuzumab (12.88%). A control group of 52 patients received chemotherapy without trastuzumab (31.90%). Patients in the subcutaneous therapy arm were older and had more advanced disease than those receiving chemotherapy only.
The patients voluntarily completed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the supplemental form BR-23, which assess a patient’s physical, role, emotional, social, and cognitive functioning, as well as symptoms and global health status.
The researchers say that their analysis did not show any significant differences in HRQOL parameters between the subcutaneous trastuzumab band intravenous trastuzumab groups.
However, the patients without comorbidities who received subcutaneous trastuzumab with their chemotherapy and endocrine therapy showed a significant improvement in emotional function, and reported that they were less upset by hair loss than the patients in the control group. In a multivariate analysis, patients receiving the subcutaneous trastuzumab who has undergone a mastectomy improved their role functioning compared with patients in the control group. (P =.021)
The authors caution that, because this study was observational in nature, the results should be interpreted with caution, and additional studies will be necessary to confirm these findings. However, they conclude that subcutaneous trastuzumab did not negative impact HRQOL in any of the parameters assessed in all subgroups of patients.
Reference
1. Syrios J, Pappa E, Volakakis N, et al. Real-world data on health-related quality of life assessment in patients with breast cancer receiving subcutaneous trastuzumab. [Published online February 20, 2018.] Breast Cancer (Auckl). doi:10.1177/1178223418758031.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.